Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 and FOLFOX-4 in First-Line Unresectable Hepatocellular Carcinoma
NCT05864105Phase 2Completed
- Sponsor
- Biotheus
- Start
- Apr 2022
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig in hepatocellular carcinoma (HCC), sponsored by Biotheus. Primary endpoint: Objective Response Rate at 2 years. Started Apr 2022; status: completed.
02
Drugs
pumitamig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05864105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864105.